Company: CERO
Filing Date: 2025-01-21
Form Type: S-1/A
Source: 0001213900-25-004742
Chunk: 103

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-01-21
Form: S-1/A
Chunk 103
---
 |

| ● | a registration statement                                                                                                                   
 with the SEC for purposes of registering (1) the resale from time to time of up to 357,737 shares of Common Stock, which consists          
 of (i) 20,557 shares of Common Stock issued to certain selling securityholders for their portion of the merger consideration in connection 
 with the consummation of the Business Combination in exchange for shares of common stock of Legacy CERo; (ii) 200,800 shares of Common     
 Stock issuable upon the conversion of shares of our Series A Preferred Stock, purchased by certain investors pursuant to the First         
 Securities Purchase Agreement; (iii) 12,520 shares of Common Stock issuable upon the conversion of shares of our Series B Preferred        
 Stock, purchased by certain investors pursuant to the Second Securities Purchase Agreement; (iv) 31,712 shares of Common Stock initially   
 issued to the Sponsor and distributed to its members in a distribution-in-kind immediately prior to the Business Combination; (v)          
 10,000 shares of Common Stock issued to the Sponsor, which are subject to forfeiture upon the vesting of the Tertiary Earnout Shares;      
 (vi) 1,850 shares of Common Stock issued to investors other than the Sponsor in a private placement concurrently with the Initial          
 Public Offering; (vii) 16,495 shares of our Common Stock issued to certain third-party vendors and service providers; (viii) 3,250         
 shares of Common Stock issuable upon the exercise of warrants to purchase shares of our Common Stock that were converted from Legacy       
 CERo warrants (as defined below) in connection with the Business Combination; (ix) 6,127 shares of Common Stock issuable upon the          
 exercise of warrants to purchase shares of our Common Stock sold to certain investors pursuant to the First Securities Purchase Agreement; 
 (x) 50,000 shares of Common Stock issuable upon the exercise of warrants to purchase shares of our Series A Preferred Stock sold           
 to certain investors pursuant to the First and Second Securities Purchase Agreement and conversion of the underlying shares of Series      
 A Preferred Stock into Common Stock and (xi) 4,425 shares of Common Stock issuable upon the exercise of Private Placement Warrants         
 to purchase shares of our Common Stock, at an exercise price of $1,150.00 per share, that were originally sold in a private placement      
 concurrently with the Initial Public Offering; and (2) the issuance by us of up to 87,500 shares of